Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Differences in Progression and Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis at Large Urban Medical Centers

Blood (2022) 140 (Supplement 1): 9431–9433.

https://doi.org/10.1182/blood-2022-170921

Published: 2022

Journal Articles

Cutaneous/ Subcutaneous Involvement - an Immune privileged Site Associated with Poor Outcomes in Systemic Peripheral T/ NK Cell Lymphoma.

Blood (2022) 140 (Supplement 1): 12005–12007.

https://doi.org/10.1182/blood-2022-170750

Published: 2022

Journal Articles

Lacutamab in Patients with Advanced Sezary Syndrome: Results from an Interim Analysis of the Tellomak Phase 2 Trial

Martine Bagot, Youn H. Kim, Pablo L. Ortiz-Romero, Pier Luigi Zinzani, Neha Mehta-Shah, Olivier Dereure, Marie Beylot-Barry, Stéphane Dalle, Eric D Jacobsen, Auris Huen, Andrea Combalia, Maxime Battistella, Alejandro A. Gru, Hélène Moins-Teisserenc, Michael S. Khodadoust, Julien Viotti, Christine Paiva, Marianna Muller, Pierluigi Porcu

Blood (2022) 140 (Supplement 1): 3760–3761.

https://doi.org/10.1182/blood-2022-160239

Published: 2022

Journal Articles

Prognostic Significance of Cutaneous Angioimmunoblastic T-Cell Lymphoma: Correlation of Clinical, Histologic and Immunophenotypic Features with Response

Christopher N Nguyen, Rishab Prakash, Madeleine Duvic, Meghan Heberton, Julia Dai, Ranjit Nair, Luis Enrique Malpica Castillo, Carlos Torres Cabala, Lei Feng, Swaminathan Padmanabhan Iyer, Auris Huen

Blood (2022) 140 (Supplement 1): 9406–9407.

https://doi.org/10.1182/blood-2022-163810

Published: 2022

Journal Articles

Outcomes of Patients with Extranodal Natural Killer/T-Cell Lymphoma: Single Institution Series

Blood (2021) 138 (Supplement 1): 4536.

https://doi.org/10.1182/blood-2021-154347

Published: 2021

Journal Articles

No Difference in Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis

Pamela Allen, Subir Goyal, Irl Brian Greenwell, Jane Scribner, Sunil Rangarajan, Amitkumar Mehta, Colin Burke O'Leary, Tim Niyogusaba, Auris Huen, Jeffrey M. Switchenko, Erica Shantha Tarabadkar, Amy Ayers, Shalini Krishnasamy, Pierluigi Porcu, Tarsheen Sethi, Swaminathan P Iyer, Mary Jo Lechowicz

Blood (2021) 138 (Supplement 1): 2441.

https://doi.org/10.1182/blood-2021-151911

Published: 2021

Journal Articles

Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma: Final Results from a Phase I/II Open Label Multi-Center Study

Swaminathan P Iyer, Auris Huen, Weiyun Z. Ai, Deepa Jagadeesh, Mary Jo Lechowicz, Craig Okada, Tatyana A. Feldman, Suchitra Sundaram, Juan Pablo Alderuccio, Nishitha Reddy, Don Stevens, Timothy M. Kuzel, Ann Mohrbacher, Kasi Viswanath Routhu, Prajak Barde, Ajit Mohanchandran Nair, Brad M. Haverkos

Blood (2021) 138 (Supplement 1): 1365.

https://doi.org/10.1182/blood-2021-145851

Published: 2021

Journal Articles

A Multi-Center, Open Label, Phase I/II Study to Assess the Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma

Swami P. Iyer, MD, Auris Huen, MD, Bradley Haverkos, MD MPH, MS, Weiyun Z. Ai, Craig Okada, MD PhD, Timothy M. Kuzel, MD, Mary Jo Lechowicz, MD, Juan Pablo Alderuccio, MD, Ann Mohrbacher, MD, Don A. Stevens, MD, Ryan A. Wilcox, MD, Tatyana A. Feldman, MD, Suchitra Sundaram, MD, Deepa Jagadeesh, MDMPH, Nishitha Reddy, MD MSCI, Kasi Viswanath Routhu, PhD, Prajak Barde, MD, Ajit Mohanchandran Nair, PhD

Blood (2020) 136 (Supplement 1): 8–10.

https://doi.org/10.1182/blood-2020-136018

Published: 2020

Journal Articles

Characterization and Outcomes in Patients with Mogamulizumab-Associated Skin Reactions in the MAVORIC Trial

Amy C.M. Musiek, MD, Sean Whittaker, MD, Steven M. Horwitz, MD, Martine Bagot, MD PhD, Auris Huen, MD PharmD, David C. Fisher, MD, Paul Haun, MD MSc, Maarten H. Vermeer, MD PhD, Takahiro Ito, MSc, Karen Dwyer, BA, Fiona Herr, PhD, Youn H. Kim, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-141041

Published: 2020

Journal Articles

Final Results of Phase 1/1b Study of Tenalisib, Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma

Swaminathan P. Iyer, MD, Brad M. Haverkos, MDMPH,MS, Jasmine Zain, MD, Radhakrishnan Ramchandren, MD, Mary Jo Lechowicz, MD, Sumana Devata, MD, Neil Korman, MD, Lauren C. Pinter-Brown, MD, Kasi Viswanath Routhu, PhD, Prajak Barde, MD, Ajit Mohanchandran Nair, PhD, Auris Huen, MD

Blood (2019) 134 (Supplement_1): 2831.

https://doi.org/10.1182/blood-2019-123954

Published: 2019

Journal Articles

Safety of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome: Final Results from the Phase 3 Mavoric Study

Youn H. Kim, MD, Martine Bagot, MD PhD, Pier Luigi Zinzani, MD PhD, Madeleine Duvic, MD, Stephen Morris, MBBS, MRCP, FRCR, Ellen Kim, MD, Amy Musiek, MD, Pablo L. Ortiz-Romero, MD PhD, Craig Elmets, MD, Herbert A. Eradat, MDMS, Nina Magnolo, MD, Julia Scarisbrick, MD, Stéphane Dalle, MD PhD, David C. Fisher, MD PhD, Michi Shinohara, MD, Brian Poligone, MD PhD, Barbara Pro, MD, Pietro Quaglino, MD, Nishitha Reddy, MD MSCI, Brigitte Dreno, MD, Larisa J Geskin, MD, Ahmad S Halwani, MD, Amit Khot, MD, Marie Beylot-Barry, MD PhD, Neil Korman, MD, Frederick Lansigan, MD, Steven M. Horwitz, MD, Zanetta S. Lamar, MD, Alison J. Moskowitz, MD, Jillian Wells, MD, Oleg E. Akilov, MD PhD, Dolores Caballero, MD PhD, Richard Cowan, MBBS, MD MRCP, FRCR, Reinhard Dummer, MD, Mary Jo Lechowicz, MD, Francine M. Foss, MD, Lars Iversen, MD, Tomomitsu Miyagaki, MD PhD, Ryan Wilcox, MD, Pierluigi Porcu, MD, Maarten Vermeer, MD PhD, Sunil Abhyankar, MD, Yukihiko Kato, MD PhD, Theresa Pacheco, MD, Shigetoshi Sano, MD PhD, Basem M. William, MRCP,MD, Timothy S. Fenske, MD, Noriko Fukuhara, MD PhD, Koji Habe, MD PhD, Toshihisa Hamada, MD PhD, Eiji Kiyohara, MD PhD, Bryone J. Kuss, MBBS, PhD FRACP, FRCPA, Adam Lerner, MD, Lawrence Mark, MD PhD, Javier Munoz, MD, Hiroyuki Okamoto, MD PhD, Christiane Querfeld, MD PhD, Jiro Uehara, MD, Hisashi Uhara, MD PhD, Kentaro Yonekura, MD PhD, Auris Huen, MD, Kensei Tobinai, MD PhD, Yoshiki Tokura, MD PhD, Erin Boh, MD PhD, Jan Nicolay, MD, Hidefumi Wada, MD, Mollie Leoni, MD, Takahiro Ito, MSc, Fiona Herr, PhD, Lubomir Sokol, MD PhD

Blood (2019) 134 (Supplement_1): 5300.

https://doi.org/10.1182/blood-2019-122778

Published: 2019

Journal Articles

A Phase I/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 Mg Fixed Dose Administered Every 3 Weeks (Q3W) in Combination with Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)

Swami P. Iyer, MD, Sattva S Neelapu, MD, Ethan Burns, MD, Ranjit Nair, MBBS,MD, Chitra Hosing, MD, Yago Nieto, MD PhD, Jason R. Westin, MD, Simrit Parmar, MBBS, Nathan H. Fowler, MD, Loretta J. Nastoupil, MD MSc, Madeleine Duvic, MD, Roberto N. Miranda, MD, Hun Ju Lee, Felipe Samaniego, MD, Sairah Ahmed, MD, Feng Lei, MS, Auris Huen, MD

Blood (2019) 134 (Supplement_1): 1546.

https://doi.org/10.1182/blood-2019-132278

Published: 2019

Journal Articles

Phase 1 Trial of Cobomarsen, an Inhibitor of Mir-155, in Cutaneous T Cell Lymphoma

Blood (2018) 132 (Supplement 1): 2903.

https://doi.org/10.1182/blood-2018-99-119861

Published: 2018

Journal Articles

Pooled Safety Analysis and Efficacy of Tenalisib (RP6530), a PI3Kδ/γ Inhibitor, in Patients with Relapsed/Refractory Lymphoid Malignancies

Swami P. Iyer, MD, Auris Huen, MD, Andres J M Ferreri, MD, Bradley M. Haverkos, MD MPH, MS, Jasmine M. Zain, MD, Radhakrishnan Ramchandren, MD, Mary Jo Lechowicz, MD, Sumana Devata, MD, Neil Korman, MD, Lauren C. Pinter-Brown, MD, Richard Delarue, MD, Kasi V Routhu, PhD, Prajak Barde, MD, Ajit M Nair, PhD, Carmelo Carlo-Stella, MD

Blood (2018) 132 (Supplement 1): 2925.

https://doi.org/10.1182/blood-2018-99-112757

Published: 2018

Journal Articles

Evaluation of Symptom and Side Effect Bother in Cutaneous T-Cell Lymphoma Patients Treated with Mogamulizumab or Vorinostat

Stacie Hudgens, MA, Pierluigi Porcu, MD, Pietro Quaglino, MD, Auris Huen, MD, Lysbeth Floden, PhD, Mollie Leoni, MD, Madeleine Duvic, MD

Blood (2018) 132 (Supplement 1): 3592.

https://doi.org/10.1182/blood-2018-99-116346

Published: 2018

Journal Articles

Safety and Anti-Tumour Activity of RP6530, Dual PI3K δ/γ Inhibitor, in Relapsed/Refractory T-Cell Lymphoma: Updated Results from the Dose Expansion Cohort of an on-Going Phase I/Ib Study

Yasuhiro Oki, MD, Jasmine Zain, MD, Bradley M. Haverkos, MD MPH, MS, Neil Korman, MD, Lauren Pinter-Brown, MD, Sumana Devata, MD, Rod Ramchandren, MD, Mary Jo Lechowicz, MD, Prajak Barde, MD, Ajit Nair, PhD, Auris Huen, MD

Blood (2017) 130 (Supplement 1): 2791.

https://doi.org/10.1182/blood.V130.Suppl_1.2791.2791

Published: 2017

Journal Articles

A Dose Escalation Study of RP6530, a Novel Dual PI3K δ/γ Inhibitor, in Patients with Relapsed/Refractory T-Cell Lymphoma

Yasuhiro Oki, MD, Auris Huen, MD, Prajak J Barde, MD, Kumar Penmetsa, PhD, Alda Ashu, Little Pullokaran, Carol Wilson, Srikant Viswanadha, PhD, Madeleine Duvic, MD

Blood (2016) 128 (22): 3004.

https://doi.org/10.1182/blood.V128.22.3004.3004

Published: 2016

Journal Articles

Effects of Aprepitant on Drug Metabolism in Lymphoma Patients Receiving Multi-Day Chemotherapy Regimen of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, + Rituxan (R/CHOP): Randomized, Cross-Over Study

Saroj Vadhan-Raj, MD, Ivan Spasojevic, Ph.D., Xiao Zhou, MD, PHD, Jorge E Romaguera, MD, Michelle A. Fanale, MD, Luis E Fayad, MD, Nathan H. Fowler, MD, Auris Huen, PHARMD, F.B. Hagemeister, MD, Maria Alma Rodriguez, MD, Sattva S. Neelapu, MD, Felipe Samaniego, MD, Anas Younes, MD, Larry W Kwak, MD, PhD

Blood (2011) 118 (21): 1613.

https://doi.org/10.1182/blood.V118.21.1613.1613

Published: 2011

Journal Articles

Higher Incidence of Venous Thromboembolism Is Associated with Initial Cycles of Chemotherapy in Lymphoma Patients: Creatinine and Hemoglobin as Key Risk Factors.

Xiao Zhou, MD, Auris Huen, Pharm, Shyam Teegala, MD, Yuan Ji, MD, Luis Fayad, MD, F.B. Hagemeister, MD, Saroj Vadhan-Raj, MD

Blood (2007) 110 (11): 3993.

https://doi.org/10.1182/blood.V110.11.3993.3993

Published: 2007

Journal Articles

Baseline Osteopenia and Osteoporosis in Untreated Non-Hodgkin’s Lymphoma Patients.

Michael A. Thompson, MD, PhD, Auris Huen, PharmD, Gregory D. Ayers, MS, Bela B. Toth, DDS, Rena V. Sellin, MD, Ana O. Hoff, MD, William A. Murphy, Jr., MD, F.B. Hagemeister, MD

Blood (2006) 108 (11): 4607.

https://doi.org/10.1182/blood.V108.11.4607.4607

Published: 2006

NARROW

Differences in Progression and Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis at Large Urban Medical Centers

Cutaneous/ Subcutaneous Involvement - an Immune privileged Site Associated with Poor Outcomes in Systemic Peripheral T/ NK Cell Lymphoma.

Lacutamab in Patients with Advanced Sezary Syndrome: Results from an Interim Analysis of the Tellomak Phase 2 Trial

Prognostic Significance of Cutaneous Angioimmunoblastic T-Cell Lymphoma: Correlation of Clinical, Histologic and Immunophenotypic Features with Response

Outcomes of Patients with Extranodal Natural Killer/T-Cell Lymphoma: Single Institution Series

No Difference in Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis

Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma: Final Results from a Phase I/II Open Label Multi-Center Study

A Multi-Center, Open Label, Phase I/II Study to Assess the Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma

Characterization and Outcomes in Patients with Mogamulizumab-Associated Skin Reactions in the MAVORIC Trial

Final Results of Phase 1/1b Study of Tenalisib, Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma

Safety of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome: Final Results from the Phase 3 Mavoric Study

A Phase I/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 Mg Fixed Dose Administered Every 3 Weeks (Q3W) in Combination with Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)

Phase 1 Trial of Cobomarsen, an Inhibitor of Mir-155, in Cutaneous T Cell Lymphoma

Pooled Safety Analysis and Efficacy of Tenalisib (RP6530), a PI3Kδ/γ Inhibitor, in Patients with Relapsed/Refractory Lymphoid Malignancies

Evaluation of Symptom and Side Effect Bother in Cutaneous T-Cell Lymphoma Patients Treated with Mogamulizumab or Vorinostat

Safety and Anti-Tumour Activity of RP6530, Dual PI3K δ/γ Inhibitor, in Relapsed/Refractory T-Cell Lymphoma: Updated Results from the Dose Expansion Cohort of an on-Going Phase I/Ib Study

A Dose Escalation Study of RP6530, a Novel Dual PI3K δ/γ Inhibitor, in Patients with Relapsed/Refractory T-Cell Lymphoma

Effects of Aprepitant on Drug Metabolism in Lymphoma Patients Receiving Multi-Day Chemotherapy Regimen of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, + Rituxan (R/CHOP): Randomized, Cross-Over Study

Higher Incidence of Venous Thromboembolism Is Associated with Initial Cycles of Chemotherapy in Lymphoma Patients: Creatinine and Hemoglobin as Key Risk Factors.

Baseline Osteopenia and Osteoporosis in Untreated Non-Hodgkin’s Lymphoma Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only